Intensification of antiviral therapy for chronic hepatitis B with autoleukocyte immunization.

Oleksandr B Herasun
{"title":"Intensification of antiviral therapy for chronic hepatitis B with autoleukocyte immunization.","authors":"Oleksandr B Herasun","doi":"10.2174/1872214812666180507095457","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The article presents a new method of intensification of antiviral therapy for chronic hepatitis B with intradermal autoleukocyte immunization during treatment with a drug of nucleotide analogues - tenofovir (patent UA 113873 U, 2017); other curative vaccines for chronic hepatitis B are also regarded.</p><p><strong>Objective: </strong>The research involves patients with chronic hepatitis B (30), whose replication of HBV DNA decreased to a certain level after long-lasting (over 2 years) antiviral therapy, its further reduction ceased. These patients underwent intradermal autoleukocyte immunization for intensification of antiviral therapy.</p><p><strong>Method: </strong>Leukocytes were isolated from plasma of a patient's heparinized venous blood by centrifuging at 400 g for 8 minutes, after that the precipitate was resuspended in 1-1.5 ml of own blood serum and injected intradermally into the back in the dose 0.1 ml. Immunization was conducted at least 3 times with 30-40-day interval.</p><p><strong>Results: </strong>Due to autoleukocyte immunization, the process of further decrease in virus reproduction resumed in 24 patients (out of 30; 80%). Out of six other patients (20%), in whom HBV DNA was detected only by supersensitive PCR method (sensitivity to 5 IU/ml) after long-lasting antiviral therapy, a negative result on examination was achieved in 2 individuals (33.33%).</p><p><strong>Conclusion: </strong>Autoleukocyte immunization intensifies efficiency of antiviral therapy for chronic hepatitis B with a drug from the group of nucleotide analogues.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on endocrine, metabolic & immune drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872214812666180507095457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The article presents a new method of intensification of antiviral therapy for chronic hepatitis B with intradermal autoleukocyte immunization during treatment with a drug of nucleotide analogues - tenofovir (patent UA 113873 U, 2017); other curative vaccines for chronic hepatitis B are also regarded.

Objective: The research involves patients with chronic hepatitis B (30), whose replication of HBV DNA decreased to a certain level after long-lasting (over 2 years) antiviral therapy, its further reduction ceased. These patients underwent intradermal autoleukocyte immunization for intensification of antiviral therapy.

Method: Leukocytes were isolated from plasma of a patient's heparinized venous blood by centrifuging at 400 g for 8 minutes, after that the precipitate was resuspended in 1-1.5 ml of own blood serum and injected intradermally into the back in the dose 0.1 ml. Immunization was conducted at least 3 times with 30-40-day interval.

Results: Due to autoleukocyte immunization, the process of further decrease in virus reproduction resumed in 24 patients (out of 30; 80%). Out of six other patients (20%), in whom HBV DNA was detected only by supersensitive PCR method (sensitivity to 5 IU/ml) after long-lasting antiviral therapy, a negative result on examination was achieved in 2 individuals (33.33%).

Conclusion: Autoleukocyte immunization intensifies efficiency of antiviral therapy for chronic hepatitis B with a drug from the group of nucleotide analogues.

通过自身白细胞免疫加强慢性乙型肝炎的抗病毒治疗。
导言:文章介绍了在使用核苷酸类似物药物--替诺福韦(专利号 UA 113873 U, 2017 年)治疗期间通过皮内自身白细胞免疫加强慢性乙型肝炎抗病毒治疗的新方法;同时还考虑了其他治疗慢性乙型肝炎的疫苗:研究对象为慢性乙型肝炎患者(30 例),这些患者在接受长期(2 年以上)抗病毒治疗后,HBV DNA 复制量下降到一定水平,但随后又停止下降。这些患者接受了皮内自体白细胞免疫,以加强抗病毒治疗:方法:从患者肝素化静脉血的血浆中分离白细胞,400 克离心 8 分钟,然后将沉淀物重悬于 1-1.5 毫升自身血清中,以 0.1 毫升的剂量皮内注射到患者背部。免疫至少进行 3 次,每次间隔 30-40 天:结果:由于进行了自体白细胞免疫,24 名患者(共 30 人,占 80%)的病毒繁殖进一步减少。另外 6 名患者(20%)在接受长期抗病毒治疗后仅通过超敏 PCR 方法(灵敏度为 5 IU/ml)检测到 HBV DNA,其中 2 人(33.33%)的检查结果为阴性:结论:自体白细胞免疫可提高核苷酸类似物类药物抗病毒治疗慢性乙型肝炎的效率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信